Aspira Women’s Health is a bio-analytical-based women’s health company and is focused on gynecological disease diagnostic tools. They have announced that they have entered into a securities purchase agreement dated June 30, 2024, with existing accredited shareholders and company insiders to sell an aggregate of 1,264,739 shares of its common stock at an offering price of $1.53 per share and warrant through a private placement financing.
“The strong participation in this financing by our existing shareholders demonstrates firm support for Aspira at an important point in our growth,” said Nicole Sandford, Aspira’s CEO. “We are laser-focused on commercial growth following the expansion of our OvaSuite test portfolio and the publication of compelling clinical data earlier this quarter. We believe we are well on our way to changing the standard of care for the 1.2 to 1.5 million U.S. women diagnosed with an adnexal mass each year.”
Aspira Women’s Health is not permitted to offer or sell securities in the United States unless an effective registration statement or an applicable exemption from the registration requirements is in place. The securities being issued and sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws. Aspira has committed to registering the resale of the common stock shares issued in the private placement by filing a registration statement with the Securities and Exchange Commission.
